Clear-cell ovarian carcinoma

Wang H, Kachman MT, Schwaratz DR, Cho KR, Lubman DM. A protein molecular weight map of ES2 clear cell ovarian carcinoma cells using a two-dimensional liquid separations/mass mapping technique. Electrophoresis 2002 23 3618-81. 

CD9 Papillary (chromophile) renal cell carcinoma, clear cell renal cell carcinoma, Pre B-ALL, AML (M3) Astrocytoma, ovarian carcinoma, vascular tumors B-cells, plasma cells, activated T-ceUs, megakaryocytes/ platelets, macrophages, granulocytes, endodielial cells, brain, cardiac... 

Lin F, Zhang PL, Yang XJ, Shi J, BlasickT, Han WK, Wang HL, Shen SS, Teh BT, Bonventre JV Human kidney injury molecule-1 (hKIM-1) A useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 31 371 -381,2007. 

Cameron RI, Ashe P, O Rourke DM, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Ini J Gynecol Pathol. 2003 22 272-276. 

Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 1998 22 805-815. 

Nuclear expression HNF-113 may emerge as a specific marker for endometrial and ovarian clear cell carcinoma. 

Ramalingam P, Malpica A, Silva EG, et al. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004 28 1499-1505. 

Shimizu M, Nikaido T, Toki T, et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer. 1999 85 669-677. 

Mikami Y, Hata S, Melamed J, et al. Basement membrane material in ovarian clear cell carcinoma Correlation with growth pattern and nuclear grade. Int J Gynecol Pathol. 1999 18 52-57. 

Hepatocyte nuclear factor-ip (HNF-ip) is a transcription factor that directly binds to DNA and is shown to be unregulated in ovarian clear cell carcinomas for unknown reasons. Mesothelial cells and non-clear cell adenocarcinomas are shown to be negative. A distinct nuclear staining is shown in clear cell carcinomas and is considered to be a positive result. HNF-ip is useful in peritoneal fluid cytology to distinguish clear cell carcinomas from other adenocarcinomas. Future studies are needed to evaluate the sensitivity and specificity of this marker in other cytology samples. 

Kato N, Toukairin M, Asanuma I, et al. Immunocytochemis-tty fot hepatocyte nucleat factor-lbeta (HNF-lbeta) A marker for ovarian clear cell carcinoma. Diagn Cytopathol. 2007 35 193-197. 

Clear cell carcinoma -Brenner tumor and ovarian transitional cell carcinoma ... 

Clear cell carcinomas present approximately 2%-7% of all ovarian cancers. Seventy-five percent of patients are diagnosed with stage I disease however. 

Fig. 10.19. Clear cell carcinoma. Parasagittal T2-weighted image shows a large, well-delineated cystic ovarian lesion cepha-lad of the bladder (B), which extends to the midlumbar region. At its anterior wall, broad-based protruding nodules (arrow) with a thickness of more than 2 cm are demonstrated, a typical finding of an ovarian malignancy. Courtesy of Dr. M.T. Cunha, Lisbon...

Hricak H, Reinhold QAscher SM (2004) Ovarian clear cell carcinoma. In Hricak H, Reinhold C, Ascher SM (eds) Gynecology top 100 diagnoses. WB Saunders Company, Amir-sys. Salt Lake City, pp 104-106... 

Under the conditions of the study, there was clear evidence of carcinogenicity in rats as shown by squamous cell and basal cell neoplasms of the skin and in mice as shown by squamous cell carcinomas of the skin and ovarian neoplasms in females. No information has been reported on the carcinogenicity of VCD in humans. 

The mechanism of L-1210 resistance to cisplatin and other platinum antitumour agents remains to be clearly defined. Both Waud [77] and others [78] suggest that reduced cisplatin uptake may be responsible in part for the resistance of the cell line. It has also been found that glutathione levels are high in human ovarian carcinoma cells made resistant to cisplatin in vitro [79]. However, reduction in the level did not alter the resistance to the drug [80]. Decreases in amino-acid transport and changes in amino-acid substrate specificities have also been suggested as the basis for the resistance [81], but definitive evidence has been difficult to obtain. 

---